EN
Home/Answers/GLP-1s and A1C
ALLAll countries Medicines

How much do tirzepatide and semaglutide lower A1C?

What we checked11 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

In the US label trials, semaglutide (Ozempic) lowered A1C by 1.4 to 1.6 points and tirzepatide (Mounjaro) by 1.7 to 1.8 points, from about 8%, against 0.1 on placebo. In a head-to-head trial, tirzepatide lowered it slightly more. Up to 1 in 5 people felt sick on the higher doses.

How much did A1C fall in the placebo trials?

In the main placebo trials, A1C (HbA1c) fell by 1.4 to 1.8 points from a start of about 8%, against 0.1 points on placebo.1,2

Semaglutide (Ozempic). A 30-week trial included 388 adults whose diabetes was not controlled by diet and exercise. They took Ozempic 0.5 mg, 1 mg or a dummy injection (placebo). A1C fell 1.4 and 1.6 points, against 0.1 on placebo.1 An A1C below 7% was reached by 73% and 70%, against 28%.1

Tirzepatide (Mounjaro). In a 40-week trial of 478 similar adults, A1C fell 1.8, 1.7 and 1.7 points on 5, 10 and 15 mg, against 0.1 on placebo.2 Below 7% was reached by 78% to 85%, against 23%.2

These are averages. In the Ozempic trial, about 3 in 10 people on the medicine did not get below 7%.1

Does tirzepatide lower A1C more than semaglutide?

Slightly, in one trial. Over 40 weeks, A1C fell 2.0 to 2.3 points on Mounjaro, against 1.9 points on Ozempic 1 mg.2

The SURPASS-2 trial gave 1,879 adults already taking metformin either Mounjaro 5, 10 or 15 mg or semaglutide 1 mg. Their A1C started at about 8.3%.2 Below 7% was reached by 82% to 86% on Mounjaro and 79% on semaglutide.2

People knew whether they took Mounjaro or semaglutide (open-label), and Eli Lilly, which makes Mounjaro, paid for the trial.3 It did not test Ozempic 2 mg.2 In a separate trial of 961 adults, Ozempic 2 mg lowered A1C by 2.1 points, against 1.9 on 1 mg.1

How quickly does A1C fall, and does a higher dose help?

An A1C test reflects your average blood sugar over the past 3 months, so a change takes months to show in full.4

Doses start low to limit stomach side effects.1,2 The US Ozempic label starts at 0.25 mg for 4 weeks, then 0.5 mg. It lists 0.5, 1 and 2 mg as the doses for blood sugar control.1 The US Mounjaro label starts at 2.5 mg and adds 2.5 mg steps, at least 4 weeks apart, up to 15 mg.2

Higher doses added little on average. In the Mounjaro placebo trial, 5 mg and 15 mg lowered A1C by similar amounts, 1.8 and 1.7 points. Nausea was more common on the higher dose, 18% against 12%.2

Some things make a result less accurate. Very low iron can give a falsely high A1C, says the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).4

Do Wegovy and Zepbound lower A1C too?

Yes. Wegovy is semaglutide and Zepbound is tirzepatide. In trials of adults with type 2 diabetes, A1C fell 1.6 points on Wegovy and 2.1 on Zepbound.5,6

A 68-week trial included 807 adults with type 2 diabetes and a BMI of 27 or more. From about 8.1%, A1C fell 1.6 points on Wegovy 2.4 mg, against 0.4 on placebo.6 In a 72-week trial of 938 similar adults, A1C fell 2.1 points on Zepbound 10 or 15 mg, against 0.5 on placebo.5

Neither US label lists type 2 diabetes as a use. Both list weight management.5,6

RisksThe risks, in brief
  • Feeling sick (nausea) affected 20% on Ozempic 1 mg against 6% on placebo, and 18% on Mounjaro 15 mg against 4%.1,2
  • Stopping for stomach side effects was 3.1% to 3.8% on Ozempic and 3.0% to 6.6% on Mounjaro, against 0.4% on placebo.1,2
  • Low blood sugar is more likely, including severe lows, with insulin or a sulfonylurea. With insulin, 1.5% on Ozempic 1 mg had a low that needed another person's help.1,2
  • Diabetic eye disease (retinopathy) can worsen for a while when blood sugar improves fast. In a 2-year trial, eye complications were 3.0% on Ozempic against 1.8% on placebo.1
  • Inflamed pancreas (pancreatitis) is a labelled risk. Its sign is severe stomach pain that will not go away, sometimes felt in the back.1
GLP-1 side effects (US guide; see your country below) →

What do people on tirzepatide or semaglutide report about A1C?

From public patient forums: 242 Reddit threads in r/Mounjaro, r/mounjarouk, r/Ozempic, r/Zepbound, r/Semaglutide and r/WegovyWeightLoss, read October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the label Many describe large A1C falls, mostly from high starting points. In the US label trials, average falls were 1.4 to 2.3 points from about 8%.1,2
  • Matches the label Several saw little change on the starting dose and more after stepping up. The US Ozempic label calls 0.25 mg a starting dose and lists 0.5 mg and above for blood sugar control.1
  • Matches the label Several had a slow or partial response, or an A1C that stalled. In the Ozempic placebo trial, about 3 in 10 on the medicine did not get below 7%.1
  • Matches the label Several had real lows, mostly when also taking insulin or a sulfonylurea. Both US labels say these combinations raise the risk of low blood sugar.1,2
  • Matches the label Several had nausea or other stomach effects early on or after a dose increase, which usually settled. The US Mounjaro label says most happened during dose increases and eased over time.2

Advice people share

  • Matches the label Several advise agreeing any change to insulin or a sulfonylurea with the prescriber, not making it alone. Both US labels say lower doses of those medicines may cut the risk of lows.1,2
  • Matches the NIDDK Several suggest waiting about 3 months before judging A1C. The test reflects average blood sugar over the past 3 months.4
  • Label says otherwise Several mention stretching the gap between doses or taking partial doses from pens. The US Mounjaro label gives one dose once a week, starting at 2.5 mg and rising in 2.5 mg steps at least 4 weeks apart.2

In your country

The trials are the same everywhere. Some labels report them with a different analysis, and the highest dose sold differs by country.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Mounjaro label reports the SURPASS-1 trial with a different analysis, so its falls look larger: 1.87 to 2.07 points, against a rise of 0.04 on placebo.9

Emergency number: 000

Type 2 diabetes and GLP-1 medicines in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The answer above applies.

Emergency number: 911

Type 2 diabetes and GLP-1 medicines in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The EU Mounjaro label counts only time on treatment without extra (rescue) medicine, so its SURPASS-1 falls look larger: 1.87 to 2.07 points, against a rise of 0.04 on placebo.7

Emergency number: 15 or 112

Diabète de type 2 et GLP-1 (en français)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The EU Mounjaro label counts only time on treatment without extra (rescue) medicine, so its SURPASS-1 falls look larger: 1.87 to 2.07 points, against a rise of 0.04 on placebo.7

Emergency number: 112

Typ-2-Diabetes und GLP-1-Medikamente (auf Deutsch)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We could not open an Indian label, so this page relies on the US labels. A December 2025 report says Ozempic is sold in India in 0.25, 0.5 and 1 mg strengths, so the 2 mg result above does not apply there.10

Emergency number: 112

Type 2 diabetes and GLP-1 medicines in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a Saudi label, so this page relies on the US labels.

Emergency number: 997 or 911

Type 2 diabetes and GLP-1 medicines in Saudi Arabia (in Arabic)

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a UAE label, so this page relies on the US labels.

Emergency number: 998 for an ambulance, or 999

Type 2 diabetes and GLP-1 medicines in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Mounjaro label counts only time on treatment without extra (rescue) medicine, so its SURPASS-1 falls look larger: 20.4 to 22.7 mmol/mol (1.87 to 2.07 points), against a rise of 0.4 mmol/mol on placebo.8

Emergency number: 999

Type 2 diabetes and GLP-1 medicines in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Type 2 diabetes and GLP-1 medicines in the US

Get help now: call your local emergency number for fainting, sudden dizziness or weakness, confusion, unusual behaviour or difficulty waking, or severe or persistent vomiting or diarrhoea.11 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, sometimes felt in your back, or changes in your vision.1

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, sections 2.2, 5.2, 5.3, 5.5, 6.1 (Tables 1 and 2) and 14.1 (Tables 3 and 7) (US label). PDF
  2. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, sections 2.1, 5.3, 6.1 (Table 1) and 14.2–14.3 (Tables 4 and 5) (US label). PDF
  3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503–15. Open-label. Funded by Eli Lilly. DOI · PMID 34170647
  4. US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The A1C test & diabetes. Last reviewed April 2018. Link
  5. Eli Lilly. Zepbound (tirzepatide) US prescribing information, sections 1 and 14 (Study 2, Table 3) (US label). PDF
  6. Novo Nordisk. Wegovy (semaglutide) US prescribing information, sections 1 and 14 (Study 3) (US label). DailyMed
  7. European Medicines Agency. Mounjaro: EU summary of product characteristics, section 5.1 (SURPASS-1, Table 2) (EU label). PDF
  8. Eli Lilly. Mounjaro KwikPen: UK summary of product characteristics, section 5.1 (SURPASS 1, Table 2) (UK label). emc
  9. Eli Lilly. Mounjaro (tirzepatide) Australian Product Information, version A14.0, October 2026, section 5.1 (SURPASS 1, Table 6) (Australian label). PDF
  10. Business Standard. Novo Nordisk launches Ozempic in India amid patent battles. 12 December 2025 (news report, not a label). Link
  11. American College of Emergency Physicians. Know when to go: adult medical emergency symptoms. Link

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between Nov 9 and Nov 16, 2026. Trial figures come from the US labels' own tables; the “3 in 10” figure is our own arithmetic. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write